选择性孕激素受体调节剂治疗子宫平滑肌瘤
子宫平滑肌瘤是常见良性肿瘤,可致经期延长、盆腔压迫及生殖障碍。手术为主要治疗,药物如促性腺激素释放激素激动剂和拮抗剂效果有限且副作用多。选择性孕激素受体调节剂近期显示可缩小肌瘤并延长临床效果,为有前景的新选择。
要点
- 子宫平滑肌瘤常见症状包括经期延长、盆腔压迫和生殖障碍。
- 促性腺激素释放激素激动剂和拮抗剂治疗症状性肌瘤仅部分成功。
- 选择性孕激素受体调节剂显示缩小肌瘤和延长临床效果的前景。
核心结论
- 选择性孕激素受体调节剂为子宫平滑肌瘤的药物治疗带来希望,是有前景的新选择。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 选择性孕激素受体调节剂治疗显示缩小子宫平滑肌瘤和延长临床效果的前景。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uterine leiomyomas have drawn much attention since being described more than 200 years ago. These common benign uterine tumors often present with prolonged menstrual bleeding, pelvic pressure, and reproductive disorders and pose a true financial burden on health care systems all over the world. Over the past few decades, surgical treatment of uterine leiomyomas has received most of the focus compared with other treatment options. Choosing the appropriate surgical technique depends on many factors such as uterine leiomyoma location, patient's age, interest in future fertility, concomitant comorbidities, and the patient's preference. Pharmacologic treatments such as gonadotropin-releasing hormone agonists and antagonists have been used for the treatment of symptomatic uterine leiomyomas with only partial success. Myriad side effects and limited clinical results have rendered them less popular and have exposed a true need for new effective medical treatments. Recently, treatment with selective progesterone receptor modulators has shown promising results with shrinkage of uterine leiomyomas and a prolonged clinical effect. Selective progesterone receptor modulators provide hope for women with this challenging condition and are a promising new option in the armamentarium of medical treatments for uterine leiomyomas.
引用
- Safrai M, Chill HH, Reuveni Salzman A, et al. Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas. Obstet Gynecol. 2017. PMID: 28697115. doi:10.1097/AOG.0000000000002143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。